Allergologie-immunologie clinique. Nouveautés dans le traitement de l’asthme sévère [Innovations in the treatment of severe asthma]

Details

Serval ID
serval:BIB_2BCCEEBAD00E
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Allergologie-immunologie clinique. Nouveautés dans le traitement de l’asthme sévère [Innovations in the treatment of severe asthma]
Journal
Revue medicale suisse
Author(s)
Buss G., Spertini F.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
11/01/2017
Peer-reviewed
Oui
Volume
13
Number
544-545
Pages
18-19
Language
french
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
In severe asthma, there is a real need for new effective therapies offering a good safety and tolerance profile. Mepolizumab is a humanized anti-interleukin-5 monoclonal antibody, available in Switzerland since 2016 for treatment of severe adult eosinophilic asthma. Other monoclonal antibodies, such as dupilumab, are being developed in the field of asthma.

Keywords
Adult, Anti-Asthmatic Agents/therapeutic use, Antibodies, Monoclonal/therapeutic use, Antibodies, Monoclonal, Humanized/therapeutic use, Asthma/therapy, Humans, Severity of Illness Index, Therapies, Investigational/methods, Therapies, Investigational/trends
Pubmed
Create date
18/08/2017 14:56
Last modification date
20/08/2019 13:11
Usage data